New phase 3 data presented at ESMO earlier today suggests Tagrisso could be a major step forward in treating patients with EGFR positive non-small cell lung cancer. AstraZeneca has been ...
It’s now official: Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against AstraZeneca’s standard-of-care Tagrisso as a first-line ...
AstraZeneca's EGFR inhibitor Tagrisso has become the first drug in the class to be approved in the EU as a treatment for a specific form of locally advanced, unresectable non-small cell lung ...
Hosted on MSN1mon
AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLCTagrisso - A Key Top-Line Driver for AZN Tagrisso is approved in more than 100 countries worldwide, including the United States, the EU and Japan, for use in different NSCLC settings. In the first ...
Hosted on MSN1mon
AstraZeneca’s Tagrisso gains EC approval for NSCLC treatmentAstraZeneca has gained approval from the European Commission (EC) for its oral therapy, Tagrisso (osimertinib), to treat adults with locally advanced, unresectable non-small cell lung cancer (NSCLC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback